Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ5082 in Primary IgA Nephropathy
NCT06982040Phase 2Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- May 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of NTQ5082 in IgA nephropathy (IgAN), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Planned start May 2025; status: not yet recruiting.
02
Drugs
NTQ5082
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06982040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982040.